DOI QR코드

DOI QR Code

Hesperetin Inhibits Vascular Formation by Suppressing of the PI3K/AKT, ERK, and p38 MAPK Signaling Pathways

  • Kim, Gi Dae (Department of Food and Nutritional Science, Kyungnam University)
  • Received : 2014.11.07
  • Accepted : 2014.11.20
  • Published : 2014.12.31

Abstract

Hesperetin has been shown to possess a potential anti-angiogenic effect, including vascular formation by endothelial cells. However, the mechanisms underlying the potential anti-angiogenic activity of hesperetin are not fully understood. In the present study, we evaluated whether hesperetin has anti-angiogenic effects in human umbilical vascular endothelial cells (HUVECs). HUVECs were treated with 50 ng/mL vascular endothelial growth factor (VEGF) to induce proliferation as well as vascular formation, followed by treatment with several doses of hesperetin (25, 50, and $100{\mu}M$) for 24 h. Cell proliferation and vascular formation were analyzed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and tube formation assay, respectively. In addition, cell signaling related to cell proliferation and vascular formation was analyzed by western blot. Furthermore, a mouse aorta ring assay was performed to confirm the effect of hesperetin on vascular formation. Hesperetin treatment did not cause differences in HUVECs proliferation. However, hesperetin significantly inhibited VEGF-induced cell migration and tube formation of HUVECs (P<0.05). Moreover, hesperetin suppressed the expression of ERK, p38 MAPK, and PI3K/AKT in the VEGF-induced HUVECs. In an ex vivo model, hesperetin also suppressed microvessel sprouting of mouse aortic rings. Taken together, the findings suggest that hesperetin inhibited vascular formation by endothelial cells via the inhibition of the PI3K/AKT, ERK and p38 MAPK signaling.

References

  1. Patan S. 2004. Vasculogenesis and angiogenesis. Cancer Treat Res 117: 3-32. https://doi.org/10.1007/978-1-4419-8871-3_1
  2. Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307. https://doi.org/10.1038/nature10144
  3. Holderfield MT, Hughes CC. 2008. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-${\beta}$ in vascular morphogenesis. Circ Res 102: 637-652. https://doi.org/10.1161/CIRCRESAHA.107.167171
  4. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6. https://doi.org/10.1093/jnci/82.1.4
  5. Ferrara N, Kerbel RS. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974. https://doi.org/10.1038/nature04483
  6. Cristi E, Perrone G, Toscano G, Verzi A, Nori S, Santini D, Tonini G, Vetrani A, Fabiano A, Rabitti C. 2005. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol 58: 1170-1174. https://doi.org/10.1136/jcp.2004.025536
  7. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y. 2000. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-2146. https://doi.org/10.1038/sj.onc.1203533
  8. Meadows KN, Bryant P, Vincent PA, Pumiglia KM. 2004. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23: 192-200. https://doi.org/10.1038/sj.onc.1206921
  9. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. 2003. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278: 35501-35507. https://doi.org/10.1074/jbc.M302967200
  10. Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. 2006. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69: 512-519. https://doi.org/10.1016/j.cardiores.2005.09.019
  11. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. 2008. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412. https://doi.org/10.1016/j.coph.2008.08.004
  12. Garg A, Garg S, Zaneveld LJD, Singla AK. 2001. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 15: 655-669. https://doi.org/10.1002/ptr.1074
  13. Zheng Q, Hirose Y, Yoshimi N, Murakami A, Koshimizu K, Ohigashi H, Sakata K, Matsumoto Y, Sayama Y, Mori H. 2002. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J Cancer Res Clin Oncol 128: 539-546. https://doi.org/10.1007/s00432-002-0373-y
  14. Binnerup SJ, Sorensen J. 1992. Nitrate and nitrite microgradients in barley rhizosphere as detected by a highly sensitive denitrification bioassay. Appl Environ Microbiol 58: 2375-2380.
  15. Tsuda H, Ohshima Y, Nomoto H, Fujita K, Matsuda E, Iigo M, Takasuka N, Moore MA. 2004. Cancer prevention by natural compounds. Drug Metab Pharmacokinet 19: 245-263. https://doi.org/10.2133/dmpk.19.245
  16. Lam IK, Alex D, Wang YH, Liu P, Liu AL, Du GH, Lee SM. 2012. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: Identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res 56: 945-956. https://doi.org/10.1002/mnfr.201100680
  17. Choi EJ, Kim GD, Chee KM, Kim GH. 2006. Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells. Nutrition 22: 947-951. https://doi.org/10.1016/j.nut.2006.05.004
  18. Kim GD, Kim GJ, Seok JH, Chung HM, Chee KM, Rhee GS. 2008. Differentiation of endothelial cells derived from mouse embryoid bodies: a possible in vitro vasculogenesis model. Toxicol Lett 180: 166-173. https://doi.org/10.1016/j.toxlet.2008.05.023
  19. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M. 2008. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing VEGFR2 signaling. Cancer Res 68: 1843-1850. https://doi.org/10.1158/0008-5472.CAN-07-5944
  20. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. 2011. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 7: 89-104. https://doi.org/10.1038/nprot.2011.435
  21. Tozer GM, Kanthou C, Baguley BC. 2005. Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435. https://doi.org/10.1038/nrc1628
  22. Newman DJ, Cragg GM. 2004. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67: 1216-1238. https://doi.org/10.1021/np040031y
  23. Kim GD, Bae SY, Park HJ, Bae K, Lee SK. 2012. Honokiol inhibits vascular vessel formation of mouse embryonic stem cell-derived endothelial cells via the suppression of PECAM and MAPK/mTOR signaling pathway. Cell Physiol Biochem 30: 758-770. https://doi.org/10.1159/000341455
  24. Kim GD, Oh J, Park HJ, Bae K, Lee SK. 2013. Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells. Int J Oncol 43: 600-610. https://doi.org/10.3892/ijo.2013.1959
  25. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L. 1997. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57: 2916-2921.
  26. Cao Y, Cao R, Brakenhielm E. 2002. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 13: 380-390. https://doi.org/10.1016/S0955-2863(02)00204-8
  27. Tosetti F, Ferrari N, De Flora S, Albini A. 2002. 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16: 2-14. https://doi.org/10.1096/fj.01-0300rev
  28. Dorai T, Aggarwal BB. 2004. Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-140. https://doi.org/10.1016/j.canlet.2004.07.013
  29. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. 2003. Angiogenesis assays: a critical overview. Clin Chem 49: 32-40. https://doi.org/10.1373/49.1.32
  30. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. 2000. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 268: 183-191. https://doi.org/10.1006/bbrc.1999.2018
  31. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, Ding J. 2006. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69: 1226-1233. https://doi.org/10.1124/mol.105.020537
  32. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
  33. Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WM. 2008. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7: 1994-2003. https://doi.org/10.4161/cbt.7.12.6967
  34. Zheng Q, Hirose Y, Yoshimi N, Murakami A, Koshimizu K, Ohigashi H, Sakata K, Matsumoto Y, Sayama Y, Mori H. 2002. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J Cancer Res Clin Oncol 128: 539-546. https://doi.org/10.1007/s00432-002-0373-y
  35. Cross MJ, Claesson-Welsh L. 2001. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201-207. https://doi.org/10.1016/S0165-6147(00)01676-X
  36. Shiojima I, Walsh K. 2002. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250. https://doi.org/10.1161/01.RES.0000022200.71892.9F

Cited by

  1. Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans vol.61, pp.8, 2017, https://doi.org/10.1002/mnfr.201600894
  2. Honey and its Phytochemicals: Plausible Agents in Combating Colon Cancer through its Diversified Actions vol.40, pp.4, 2016, https://doi.org/10.1111/jfbc.12239
  3. Farrerol inhibited angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway vol.23, pp.7, 2016, https://doi.org/10.1016/j.phymed.2016.03.008
  4. Hesperetin and its sulfate and glucuronide metabolites inhibit TNF-α induced human aortic endothelial cell migration and decrease plasminogen activator inhibitor-1 (PAI-1) levels vol.7, pp.1, 2016, https://doi.org/10.1039/C5FO00771B
  5. Hesperetin post-treatment prevents rat cardiomyocytes from hypoxia/reoxygenation injury in vitro via activating PI3K/Akt signaling pathway vol.91, 2017, https://doi.org/10.1016/j.biopha.2017.05.003
  6. vol.8, pp.43, 2018, https://doi.org/10.1039/C8RA00956B